Verition Fund Management LLC Makes New $477,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Verition Fund Management LLC acquired a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,353 shares of the company’s stock, valued at approximately $477,000. Verition Fund Management LLC owned 0.17% of Jasper Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Ally Bridge Group NY LLC grew its holdings in shares of Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Jasper Therapeutics in the second quarter valued at approximately $740,000. American Century Companies Inc. raised its stake in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the period. MetLife Investment Management LLC increased its stake in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,873 shares in the last quarter. Finally, Wolff Wiese Magana LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at $59,000. Institutional investors own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on JSPR shares. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Evercore ISI restated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Finally, Royal Bank of Canada reduced their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $73.38.

Jasper Therapeutics Price Performance

Shares of JSPR opened at $22.47 on Thursday. The firm has a 50 day simple moving average of $20.83 and a two-hundred day simple moving average of $20.89. Jasper Therapeutics, Inc. has a one year low of $4.00 and a one year high of $31.01. The company has a market cap of $337.07 million, a P/E ratio of -4.74 and a beta of 2.18.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.